GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (STU:BT1) » Definitions » Common Stock

Biosenic (STU:BT1) Common Stock : €8.18 Mil (As of Jun. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Biosenic Common Stock?

Biosenic's quarterly common stock increased from Jun. 2023 (€5.22 Mil) to Dec. 2023 (€6.28 Mil) and increased from Dec. 2023 (€6.28 Mil) to Jun. 2024 (€8.18 Mil).

Biosenic's annual common stock increased from Dec. 2021 (€0.66 Mil) to Dec. 2022 (€4.77 Mil) and increased from Dec. 2022 (€4.77 Mil) to Dec. 2023 (€6.28 Mil).


Biosenic Common Stock Historical Data

The historical data trend for Biosenic's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Common Stock Chart

Biosenic Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.45 8.42 0.66 4.77 6.28

Biosenic Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.97 4.77 5.22 6.28 8.18

Biosenic Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Biosenic Business Description

Traded in Other Exchanges
Address
Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, BEL, 1435
Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic Headlines

No Headlines